Investment
Features
FeesSafety
Academy
More
Pluang+

Compare British American Tobacco PLC (BTI) vs Novartis AG (NVS) Price & Performance

British American Tobacco PLCTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

British American Tobacco PLC vs Novartis AG — how do they compare? British American Tobacco PLC trades at $56.79 (market cap $122.96B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 2.4× British American Tobacco PLC's market cap, and British American Tobacco PLC pays the higher dividend (5.85%). Which is the better fit depends on your goals.

BTINVS
Market Cap
$122.96B$298.18B
Sector
Consumer StaplesHealth
52-Week High
$66.70$168.62
52-Week Low
$50.39$119.31
Enterprise Value
$166.84B$339.50B
Dividend Yield
5.85%3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

British American Tobacco PLC

BTI trades at $59.33, up 1.02% today, with a bearish technical signal but strong fundamentals including a P/E of 15.15, net income margin of 24.99%, and consistent earnings beats. Recent news highlights growth in next-generation products like Velo, though restructuring and regulatory pressures persist.

The outlook is mixed: valuation appears attractive with a 5%+ dividend yield, but declining operating cash flow and bearish technicals suggest near-term headwinds. Risks include regulatory scrutiny and combustible product declines, while analyst consensus leans bullish with 12 buy ratings.

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About British American Tobacco PLC

Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.

Read more on BTI

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS